Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (71-80 of 337) with videos related to

Pageof 34
Sort By:
Biostatistics (Oxford, England)|July 18, 2022
A controlled effects approach to assessing immune correlates of protectionPeter B Gilbert, Youyi Fong, Avi Kenny, et al.
The Annals of Applied Statistics|July 3, 2023
Robust joint modelling of left-censored longitudinal data and survival data with application to HIV vaccine studiesTingting Yu, Lang Wu, Jin Qiu, et al.
Biometrics|July 5, 2023
A semiparametric Cox-Aalen transformation model with censored dataXi Ning, Yinghao Pan, Yanqing Sun, et al.
Statistics in Biosciences|May 19, 2020
Generating Survival Times Using Cox Proportional Hazards Models with Cyclic and Piecewise Time-Varying CovariatesYunda Huang, Yuanyuan Zhang, Zong Zhang, et al.
Statistics in Biopharmaceutical Research|January 23, 2023
Simulation-Based Pharmacokinetics Sampling Design for Evaluating Correlates of Prevention Efficacy of Passive HIV Monoclonal Antibody ProphylaxisLily Zhang, Peter B Gilbert, Edmund Capparelli, et al.
The Annals of Applied Statistics|July 10, 2019
NONPARAMETRIC INFERENCE FOR IMMUNE RESPONSE THRESHOLDS OF RISK IN VACCINE STUDIESKevin M Donovan, Michael G Hudgens, Peter B Gilbert
Biometrics|August 11, 2007
Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variableMichael G Hudgens, Marloes H Maathuis, Peter B Gilbert
Statistical Methods in Medical Research|April 8, 2004
Endpoints in vaccine trialsMichael G Hudgens, Peter B Gilbert, Steven G Self
Statistics in Biosciences|August 8, 2017
Estimation of Stratified Mark-Specific Proportional Hazards Models under Two-Phase Sampling with Application to HIV Vaccine Efficacy TrialsGuangren Yang, Yanqing Sun, Li Qi, et al.
Journal of Virology|December 19, 2008
Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivoW David Wick, Peter B Gilbert, Otto O Yang
Pageof 34

Showing results (71-80 of 337) with videos related to

Sort By:
Pageof 34
Biostatistics (Oxford, England)|July 18, 2022
A controlled effects approach to assessing immune correlates of protectionPeter B Gilbert, Youyi Fong, Avi Kenny, et al.
The Annals of Applied Statistics|July 3, 2023
Robust joint modelling of left-censored longitudinal data and survival data with application to HIV vaccine studiesTingting Yu, Lang Wu, Jin Qiu, et al.
Biometrics|July 5, 2023
A semiparametric Cox-Aalen transformation model with censored dataXi Ning, Yinghao Pan, Yanqing Sun, et al.
Statistics in Biosciences|May 19, 2020
Generating Survival Times Using Cox Proportional Hazards Models with Cyclic and Piecewise Time-Varying CovariatesYunda Huang, Yuanyuan Zhang, Zong Zhang, et al.
Statistics in Biopharmaceutical Research|January 23, 2023
Simulation-Based Pharmacokinetics Sampling Design for Evaluating Correlates of Prevention Efficacy of Passive HIV Monoclonal Antibody ProphylaxisLily Zhang, Peter B Gilbert, Edmund Capparelli, et al.
The Annals of Applied Statistics|July 10, 2019
NONPARAMETRIC INFERENCE FOR IMMUNE RESPONSE THRESHOLDS OF RISK IN VACCINE STUDIESKevin M Donovan, Michael G Hudgens, Peter B Gilbert
Biometrics|August 11, 2007
Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variableMichael G Hudgens, Marloes H Maathuis, Peter B Gilbert
Statistical Methods in Medical Research|April 8, 2004
Endpoints in vaccine trialsMichael G Hudgens, Peter B Gilbert, Steven G Self
Statistics in Biosciences|August 8, 2017
Estimation of Stratified Mark-Specific Proportional Hazards Models under Two-Phase Sampling with Application to HIV Vaccine Efficacy TrialsGuangren Yang, Yanqing Sun, Li Qi, et al.
Journal of Virology|December 19, 2008
Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivoW David Wick, Peter B Gilbert, Otto O Yang
Pageof 34